what this node claims
AlphaFold metrics / TLR4
Model-quality receipt for the fold. It is not biological validation.
vertical proof spine
evidence / risk instrument
55%
low debt pressure
21%
89%structurestrong
pLDDT 89.2
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, candidate, finding, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence band
- confident
- confidence pct
- 89.2
- coverage context
- missing or not linked
- interpretation
- usable fold context with explicit model-confidence limits
- pae context
- missing or not linked
- plddt avg
- 89.2
- sequence length
- 0
AlphaFold metrics visual
Confident backbone model
839 residues / min 28.11 / max 98.94 / source alphafold db
Very high
71.6%
601 residues / >=90
Confident
18.5%
155 residues / 70-89
Low
4.4%
37 residues / 50-69
Very low
5.5%
46 residues / <50
usable fold context with explicit model-confidence limits
Near-complete coverage / observed 839 of 839 residues.
- residues 1-27 / mean 41.1
- residues 818-839 / mean 39.07
- residues 656-672 / mean 58.09
- residues 627-632 / mean 62.26
proof debt register
21%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.